healthcarepharmaceuticals1.93 min read
"Wegovy: Medicare Expands Coverage for Heart-Related Benefits"
1 year ago•Source: Reuters
Healthcarepharmaceuticals News
The latest healthcarepharmaceuticals stories, summarized by AI
Featured Healthcarepharmaceuticals Stories
View original source
2.09 min•1 year ago
Amazon and Lilly Collaborate for Home Delivery of Zepbound and Other Medications
Eli Lilly has partnered with Amazon's pharmacy unit to deliver drug prescriptions through its direct-to-consumer service, LillyDirect, which was launched in January to provide migraine, diabetes, and obesity drugs, including Zepbound, directly to patients. The prescriptions will be delivered by either Amazon Pharmacy or Truepill, depending on insurance coverage and other factors. The move comes amid surging demand for weight-loss drugs, and Lilly is also considering partnering with a retail pharmacy for a pick-up option. The website also connects patients to independent telehealth providers and aims to enhance its offerings with additional medicines and service providers in the near future.
More Top Stories
2
Pliant's Bexotegrast Shows Consistent Safety and Efficacy in Liver Disease Trial
Endpoints News•1 year ago
3
"Shifting Landscape: The Future of Weight Loss Drugs in 2024"
Yahoo Finance•1 year ago
More Healthcarepharmaceuticals Stories
FDA Issues Warning to Novartis Over Misleading TV Ad for Breast Cancer Drug
Originally Published 2 years ago — by Endpoints News
The FDA issued an untitled letter to Novartis, criticizing a TV commercial for the breast cancer drug Kisqali as containing "false or misleading" information. The ad, which featured a "Long Live" tagline and ran from 2022 to September 2023, was flagged for potentially giving metastatic breast cancer patients an exaggerated impression of the drug's effectiveness in treating their condition and symptoms.
"FDA's Peter Marks Leans Toward Full Approval for Sarepta's Duchenne Gene Therapy"
Originally Published 2 years ago — by STAT
Peter Marks, the FDA's top gene therapy regulator, appears open to granting some form of full approval to Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy, Elevidys, despite the failure of a confirmatory study in October. Marks suggested that the FDA has approved products based on aggregate scale performance, indicating a potential willingness to overlook certain imperfections in the data.